South Asian cardiovascular risk assessment

Yes, you can give your clinician a short list of guideline documents and key studies that specifically address South Asian cardiovascular risk and support the use of Lp(a), ApoB, CAC, and lower BMI/waist cut‑offs. The most useful references are: - 2018/2019 ACC/AHA (AHA/ACC/Multisociety) Cholesterol & Primary Prevention Guidelines – list South Asian ancestry as a risk enhancer, recommend one‑time Lp(a) testing, ApoB measurement when triglycerides are high, and CAC scoring to refine statin decisions (J Am Coll Cardiol 2019;73:e285‑e350; Circulation 2019;140:e596‑e646). - 2022 ACC Expert Consensus Decision Pathway on Non‑statin Therapies – endorses ApoB and Lp(a) for risk assessment and treatment targets (J Am Coll Cardiol 2022;80:1366‑1418). - 2023 AHA Scientific Statement on Lipoprotein(a) – recommends universal one‑time Lp(a) measurement, especially in high‑risk groups such as South Asians (Circulation 2023;148:e282‑e294). - 2022 ESC/EAS Dyslipidemia Guidelines – support ApoB as a primary therapeutic target, Lp(a) measurement, and CAC scoring for risk refinement (Eur Heart J 2022;43:1117‑120). - 2023 ADA Standards of Care (cardiovascular risk chapter) – acknowledges ApoB and CAC in diabetes management. - 2022 WHF/International Atherosclerosis Society consensus on Lipoprotein(a) – global summary endorsing once‑in‑lifetime testing. - 2020 International Atherosclerosis Society Global Consensus on Lp(a) – thresholds and management implications. - WHO/IDF ethnicity‑specific adiposity guidance for South Asians – recommends lower BMI cut‑offs (overweight ≥23 kg/m², obesity ≥27.5 kg/m²) and waist‑circumference cut‑offs (men ≥90 cm, women ≥80 cm) (WHO Expert Consultation Lancet 2004; IDF 2005/updated). - INTERHEART South Asia and MASALA cohort studies – demonstrate higher myocardial‑infarction risk and greater atherosclerotic burden at lower BMI in South Asians (Lancet 2004;364:937‑952; J Am Coll Cardiol 2017;69:1966‑1977). - 2018 SCCT CAC Guidelines – describe use of CAC scoring to guide statin or aspirin decisions in borderline/intermediate risk (J Cardiovasc Comput Tomogr 2018;12:391‑404). When you meet the clinician, you can ask them to: 1. Order a one‑time Lp(a) test. 2. Consider ApoB (or non‑HDL‑C) as a treatment target, especially if triglycerides are elevated. 3. Use CAC scoring if overall risk is uncertain. 4. Apply South‑Asian specific BMI (≥23 kg/m² for overweight, ≥27.5 kg/m² for obesity) and waist‑circumference thresholds (≥90 cm men, ≥80 cm women) when evaluating obesity‑related risk. These references are publicly available and can be printed or emailed to support a shared, evidence‑based management plan. This information is educational and not a substitute for personalized medical advice.